Other
Bevacizumab
0
Pipeline Programs↗
30
Active Trials↗
11
Companies Involved↗
Bevacizumab is an early-stage landscape with 0 programs across 11 companies. The most active players are Roche, Zhejiang Teruisi Pharmaceutical Inc., Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
137
clinical trials
Completed57 · 42%
Unknown status28 · 20%
Recruiting17 · 12%
Terminated15 · 11%
Active, not recruiting11 · 8%
Withdrawn7 · 5%
Other2 · 1%
Clinical Trials
Trial Activity
137 trials
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT05985798·258 enrolled
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06397222·23 enrolled
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Recruiting·—·Phase 2·NCT05551208·42 enrolled
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Recruiting·—·Phase 2·NCT06643793·30 enrolled
Aflibercept and Bevacizumab for Diabetic Maculopathies
Recruiting·—·Phase 4·NCT06850571·102 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)